| Company/Division name | Takeda Pharmaceutical |
| Parent company | Takeda Pharmaceutical Company Limited |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 125 |
| Year reshoring announced: | 2024 |
| Capital investment ($): | 230 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Los Angeles |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Higher productivity, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |
